Oxaliplatin-based regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: Preliminary results of a phase II study

4184 Background: Gastric cancer is the first cause of death per cancer in China, with more than 160,000 deaths/year. At time of resection, 75–85% of gastric cancer (GC) patients (pts) are expected to have nodal involvement and are at high risk of postoperative relapse. A Phase-II trial was conducted to evaluate the benefits of surgery combined with Oxaliplatin (OXA)-based regimen as neoadjuvant and adjuvant chemotherapy, on the survival of pts with locally advanced disease. Methods: 15 pts (Stage IIIb or IV) have been enrolled by now. All pts had histologically proven gastric adenocarcinoma and no previous palliative chemotherapy. Median age: 59 years (33–69 years), male/female ratio: 10/5, performance status: 0–2. Pts received OXA 130 mg/m2 3H-infusion day 1, leucovorin (LV) 200 mg/m2 (2H-infusion) followed by 5FU 400mg/m2 (bolus) and 5FU 2.5g/m2 (22h-continuous infusion) day 1, repeated every 3 weeks. Efficacy was evaluated after 2 cycles. Results: All pts are evaluable for response with a more than 50%...